4//SEC Filing
Watkins Tim 4
Accession 0001437749-25-013340
CIK 0001855175other
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 4:21 PM ET
Size
7.9 KB
Accession
0001437749-25-013340
Insider Transaction Report
Form 4
Watkins Tim
CMO & Head of Development
Transactions
- Award
Stock Option (right to buy)
2025-04-28+26,000→ 26,000 totalExercise: $4.50Exp: 2035-04-27→ Class A Common Stock (26,000 underlying) - Award
Stock Option (right to buy)
2025-04-28+260,000→ 260,000 totalExercise: $4.50Exp: 2035-04-27→ Class A Common Stock (260,000 underlying)
Footnotes (2)
- [F1]Options granted outside of the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). One-half of the option shares vest on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.
- [F2]Options granted outside of the Plan, pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). This grant is subject to a performance-based vesting condition to be satisfied upon the achievement of a particular clinical milestone, based on such performance condition being satisfied within two years of the grant date and subject to the Reporting Person's continuous service.
Documents
Issuer
Contineum Therapeutics, Inc.
CIK 0001855175
Entity typeother
Related Parties
1- filerCIK 0002065965
Filing Metadata
- Form type
- 4
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 4:21 PM ET
- Size
- 7.9 KB